Advertisement

Topics

"Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults" Drugs and Medication Database

15:54 EST 15th February 2019 | BioPortfolio

Here are the most relevant "Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults" Drugs and Medications that we have found in our database.

More Information about "Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults" on BioPortfolio

We have published hundreds of Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults news stories on BioPortfolio along with dozens of Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Clinical Trials and PubMed Articles about Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Companies in our database. You can also find out about relevant Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Drugs and Medications on this site too.

Showing "Safety Immunogenicity Study Three Candidate Vaccines Administered Combination" Drugs and Medications 1–25 of 41

Possibly Relevant

Fluoxetine [med-health pharma, llc]

These highlights do not include all the information needed to use fluoxetine safely and effectively. See full prescribing information for fluoxetine capsules. Fluoxetine Capsules, USP for Oral Use Initial U.S. Approval: 1987

Granix [cephalon, inc.]

These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012

Ilumya [sun pharma global fze]

These highlights do not include all the information needed to use ILUMYA safely and effectively. See full prescribing information for ILUMYA. ILUMYA™ (tildrakizumab-asmn) injection, for subcutaneous use Initial U.S. Approval: 2018

Sylvant [janssen biotech, inc.]

These highlights do not include all the information needed to use SYLVANT safely and effectively. See full prescribing information for SYLVANT. SYLVANT (siltuximab) for injection, for intravenous use Initial U.S. Approval: 2014

Kineret [swedish orphan biovitrum ab (publ)]

These highlights do not include all the information needed to use KINERET safely and effectively. See full prescribing information for KINERET. KINERET® (anakinra) injection, for subcutaneous useInitial U.S. Approval: 2001

Ocrevus [genentech, inc.]

These highlights do not include all the information needed to use OCREVUS safely and effectively. See full prescribing information for OCREVUS. OCREVUS (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017

Ultomiris [alexion pharmaceuticals inc.]

These highlights do not include all the information needed to use ULTOMIRIS™ safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS™ (ravulizumab-cwvz) injection, for intravenous useInitial U.S. Approval: 2018

Engerix-b [dispensing solutions inc.]

ENGERIX-B Hepatitis B Vaccine (Recombinant)

Aimovig [amgen inc]

These highlights do not include all the information needed to use AIMOVIG safely and effectively. See full prescribing information for AIMOVIG. AIMOVIG (erenumab-aooe) injection, for subcutaneous use Initial U.S. Approval: 2018

Vinorelbine [sagent pharmaceuticals]

These highlights do not include all the information needed to use VINORELBINE INJECTION safely and effectively. See full prescribing information for VINORELBINE INJECTION. VINORELBINE injection, for intravenous useInitial U.S. Approval: 1994

Emgality [eli lilly and company]

These highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY.EMGALITY (galcanezumab-gnlm) injection, for subcutaneous useInitial U.S. Approval: 2018

Kanuma [alexion pharmaceuticals, inc.]

These highlights do not include all the information needed to use KANUMA safely and effectively. See full prescribing information for KANUMA. KANUMA (sebelipase alfa) injection, for intravenous useInitial U.S. Approval: 2015

Synagis [medimmune, llc]

These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab) injection, for intramuscular useInitial U.S. Approval: 1998

Jetrea [thrombogenics inc.]

These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection, for intravitreal injectionInitial U.S. Approval: 2012

Farydak [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK. FARYDAK (panobinostat) capsules, for oral use Initial U.S. Approval: 2015

Taltz [eli lilly and company]

These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ.TALTZ (ixekizumab) injection, for subcutaneous useInitial U.S. Approval: 2016

Ajovy [teva pharmaceuticals usa, inc.]

These highlights do not include all the information needed to use AJOVY safely and effectively. See full prescribing information for AJOVY.AJOVY (fremanezumab-vfrm) injection, for subcutaneous useInitial U.S. Approval: 2018

Repaglinide [rising health, llc]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS. REPAGLINIDE tablets, for oral use Initial U.S. Approval: 1997

Repaglinide [aurobindo pharma limited]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS. REPAGLINIDE tablets, for oral use Initial U.S. Approval: 1997

Docetaxel [amneal biosciences llc]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.   DOCETAXEL injection, for intravenous use Initial U.S. Approval: 1996

Imraldi [samsung bioepis co., ltd.]

These highlights do not include all the information needed to use IMRALDI safely and effectively. See full prescribing information for IMRALDI.IMRALDI (adalimumab-xxxx) injection, for subcutaneous useInitial U.S. Approval: YYYY IMRALDI (adalimumab-xxxx) i

Amantadine hydrochloride [physicians total care, inc.]

NA

Gamifant [novimmune sa]

These highlights do not include all the information needed to use GAMIFANT safely and effectively. See full prescribing information for GAMIFANT. GAMIFANT (emapalumab-lzsg) injection, for intravenous useInitial U.S. Approval: 2018

Entyvio [takeda pharmaceuticals america, inc.]

These highlights do not include all the information needed to use ENTYVIO safely and effectively. See full prescribing information for ENTYVIO.ENTYVIO (vedolizumab) for injection, for intravenous use Initial U.S. Approval: 2014

Docetaxel [x-gen pharmaceuticals, inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION USP (Injection Concentrate) safely and effectively. See full prescribing information for DOCETAXEL INJECTION USP (Injection Concentrate). DOCETAXEL Injection (Injection



Advertisement
Quick Search
Advertisement
Advertisement